A 1.30 mm placebo-corrected improvement in esophageal distensibility plateau sounds modest until you consider the clinical comparator: that magnitude of luminal expansion is equivalent to what an esophageal dilation procedure achieves. Dupixent reaching that benchmark in 24 weeks — through pharmacology alone, without mechanical intervention — is the structural argument buried inside the REMODEL Phase 4 data presented at DDW this week, and it reframes what “disease modification” actually means in eosinophilic esophagitis.
The trial enrolled 69 adults, randomized 2:1 to dupilumab 300 mg weekly versus placebo. The primary endpoint — change in esophageal distensibility plateau measured by EndoFLIP — landed at p<0.05 in favor of dupilumab, but the secondary endpoints were sharper. The EREFS endoscopic score dropped 4.89 points from baseline versus a 0.07-point increase on placebo (p<0.0001), capturing reductions in edema, rings, exudates, furrows, and strictures simultaneously. Histological remission at the ≤6 eos/hpf threshold hit 59% on dupilumab versus 4% on placebo. These aren't parallel signals; they are converging evidence across functional, structural, and cellular layers that IL-4/IL-13 blockade is reversing the fibroinflammatory remodeling process — not just suppressing surface inflammation.
That distinction matters for trial design in this space. EoE has historically been evaluated through symptom-based endpoints like the Dysphagia Symptom Questionnaire, which captures patient experience but not tissue architecture. REMODEL’s primary endpoint — an objective biomechanical measure of luminal compliance — sets a new evidentiary standard. Competitors developing agents in EoE now face pressure to incorporate EndoFLIP or equivalent functional imaging into pivotal designs, because payers and regulators will increasingly ask whether a drug changes the organ, not just how the patient scores a food impaction diary.
The trial continues through week 128 with open-label dupilumab for all participants, including placebo crossovers. The week 76 distensibility readout is the number to track: if the functional gains compound with prolonged IL-4/IL-13 suppression, it would constitute the first durably demonstrated disease-modifying trajectory in EoE and would substantially complicate the regulatory pathway for any agent seeking approval without comparable structural data.
Jon Napitupulu is Director of Media Relations at The Clinical Trial Vanguard. Jon, a computer data scientist, focuses on the latest clinical trial industry news and trends.
